SEC Form 4 · accession 0000950138-17-000024
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Raymond J. Furey
Officer — Chief Compliance Officer
Period of report
Jan 2, 2017
Accepted (ET)
Jan 4, 2017 · 9:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 2, 2017 | F | 102 | $49.82 | D | 6,704 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 569 shares acquired between January 7, 2016 and September 30, 2016 under the Mallinckrodt employee stock purchase plan.